Those authors suggest that treatment of high-risk patients with rituximab at the time of kidney transplant might prevent recurrent FSGS by modulating podocyte function in an SMPDL-3b-dependent manner [79]. This evidence concerns the gene SMPDL3B and focal segmental glomerulosclerosis.